# Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery

Study · id `cardio:ct-nct02618824` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02618824](<https://clinicaltrials.gov/study/NCT02618824>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02618824

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.

## Technical summary

Registry record NCT02618824. Randomized; double masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT02618824, source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)
- Start date: 2015-12 (registry gives no type) (ClinicalTrials.gov record NCT02618824, source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)
- Primary completion: 2016-08 (anticipated) (ClinicalTrials.gov record NCT02618824, source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02618824, source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)
- Countries: Indonesia (ClinicalTrials.gov record NCT02618824, source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02618824-2016-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery
- Condition: Congenital Heart Disease
- Intervention (Drug): Histidine Tryptophan Ketoglutarate Solution
- Intervention (Other): Terminal Warm Blood Cardioplegia
- Lead sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)

## Provenance

Content hash: 39742f2c6a347f5b7cf3845300749842df508dff0830e139eec6476470992f3c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
